Bamlanivimab Authorized for COVID-19 Treatment

The USFDA had issued an emergency use authorization for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. It is approved for use in COVID-19 positive patients who are 12 years and older weighing at least 40kg, and who are at high risk for progressing to severe COVID-19/ hospitalization. Bamlanivimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19.

Bamlanivimab is a monoclonal antibody that is specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells. This emergency approval is based on an interim analysis from phase two randomized, placebo-controlled, double-blind clinical trial in 465 non-hospitalized adults with mild to moderate COVID-19 symptoms. Most patients, including those receiving placebo, cleared the virus by day 11.

However, for patients at high risk of disease progression, hospitalizations and emergency room visits occurred in 3% of bamlanivimab treated patients on average compared to 10% in placebo. The emergency approval allows for bamlanivimab to be distributed and administered as a single dose IV by health care providers.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19

#Featured